← Leaderboards
Karl A Werbovetz
Clemson University
$2,499,323
Attributed
$4,506,842
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $609.6K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,506,842 · 5
By mechanism
R01$3,216,075 · 2
R21$1,290,767 · 3
Top collaborators
- Kenneth A Christensen9 shared
- Jennifer E. Golden9 shared
- James Culvin Morris9 shared
- Roger J Narayan2 shared
- Zhuo Michael Wang2 shared
Most similar at Clemson University
Same institution · by research overlap
- James Culvin Morris$3,378,560
- Kenneth A Christensen$1,261,527
- Meredith T Morris$1,916,016
- Jennifer E. Golden$8,647,439
- Kimberly Sue Paul$1,375,704
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroProteinsTrypanosoma Brucei BruceiSeriesWorld Health OrganizationSolubilityCellsLeadAntiparasitic AgentsParasitesFutureLeishmania DonovaniSmall MoleculeInnovationPermeabilityGlycosomeFlow CytometryGlucose MetabolismEvaluationGlucose UptakeMethodologyLibrariesMemberLeishmania
Grant awards (17)
Development of a multiplexed assay in kinetoplastid parasites to identify probes for glycolysis$518,827
R01 · FY2024 · AI
Development of a multiplexed assay in kinetoplastid parasites to identify probes for glycolysis$66,149
R01 · FY2024 · AI
Development of a multiplexed assay in kinetoplastid parasites to identify probes for glycolysis$524,577
R01 · FY2023 · AI
Development of a multiplexed assay in kinetoplastid parasites to identify probes for glycolysis$66,149
R01 · FY2023 · AI
Development of a multiplexed assay in kinetoplastid parasites to identify probes for glycolysis$18,826
R01 · FY2023 · AI
Development of a multiplexed assay in kinetoplastid parasites to identify probes for glycolysis$497,486
R01 · FY2022 · AI
Development of a multiplexed assay in kinetoplastid parasites to identify probes for glycolysis$223,077
R01 · FY2021 · AI
Identification of kinetoplastid parasite glucose uptake and subcellular localization inhibitors as therapeutic leads$271,486
R21 · FY2018 · AI
Biodegradable Microneedle-Based Transdermal Treatment of Cutaneous Leishmaniasis$219,424
R21 · FY2017 · AI
Identification of kinetoplastid parasite glucose uptake and subcellular localization inhibitors as therapeutic leads$184,138
R21 · FY2017 · AI
Biodegradable Microneedle-Based Transdermal Treatment of Cutaneous Leishmaniasis$193,980
R21 · FY2016 · AI
Antileishmanial Lead Optimization of Quinazolines$175,854
R21 · FY2013 · AI · contact PI
Antileishmanial Lead Optimization of Quinazolines$245,885
R21 · FY2012 · AI · contact PI
Simple, Selective Antimitotic Antiparasitic Agents$298,763
R01 · FY2007 · AI · contact PI
Simple, Selective Antimitotic Antiparasitic Agents$307,686
R01 · FY2006 · AI · contact PI
Simple, Selective Antimitotic Antiparasitic Agents$334,645
R01 · FY2005 · AI
Simple, Selective Antimitotic Antiparasitic Agents$359,890
R01 · FY2004 · AI